公司概况
铨维亚医药科技（北京）发展有限公司（C&R Research China Inc.）是韩国创信医药研究有限公司（C&R Research Inc.）在北京成立了全资子公司，子公司的成立，是顺应了全球医药研发东移的潮流必然举措，同时也标志着我们“着眼于亚太、布局于全球”的商业战略实现了质的飞跃，铨维亚中国分公司的诞生，必将为亚太区域的医药研发市场带来新的变革，并为中韩两国的制药产业支起战略合作关系的桥梁，在中韩两国之间建立双向的事业机会。
“聚全球智慧、助客户腾飞”是我们不断追求的目标，我们将借助韩国总公司来自全球的150多个厂家的600多个各期临床试验的经验，以及14年间积累的各种优势资源，用高效率、高品质的服务及合理的价位服务于亚太地区高速发展的医药研发行业。
坐落于韩国首尔市的母公司成立于1997年，是韩国历史最悠久的、以从事新药临床研究为主的合同研究组织（CRO）。从2004年到2010年保持年成长率30%以上，去年销售额在韩国本土CRO中位居榜首，被诸多跨国公司选定为指定外包组织(preferred vender)。
作为一家专业化的临床外包服务组织，我们不断通过与全球各地的合作伙伴实现强强联合，并不断在资本市场提高我们为客户服务的能力，我们和台湾知名CRO公司 Virginia Contract Research Organization合资成立了JOVIA Ltd(Joint Vision Asia) 即是最好的证明。我们将根据客户的需求，通过分工合作、资源整合，为客户提供最高性价比的全方位服务。
铨维亚医药科技（北京）发展有限公司（C&R Research China Inc.）将与全球制药企业精英同心协力，为人类的健康事业做出卓越贡献！ Company Overview
Mother company C&R Research Inc., the first CRO in Korea was incorporated in 1997 leading the development of CRO industry in Korea. We have grown continuously and rapidly at a high compound annual growth rate at over 30% from 2004 to 2010 together with the growth of CRO industry in Korea.
Now, it is the right time for us to go to overseas market together with Korean pharmaceutical and biotech companies, which have experienced structural changes in a Korea pharmaceutical and biotech industry. For our strategic movement in 2010, C&R Research China was established in Beijing following establishment of JOVIA Ltd (Joint Vision Asia) established in Hong Kong by forming joint entity with Virginia Contract Research Organization, one of leading CRO company in Taiwan. We have pursued efficient business operation in terms of speed and cost while taking care of business risk management backed by strategic alliance with capable CRO company in Asia Pacific market as well as developed countries in aspect of business development and clinical operation. We have a promising future to be positioned to be an Asia star CRO growing together with Korea pharmaceutical and biotech industry.
